Agencies, 03 October: Hyderabad-based Dr Reddy’s Laboratories para Drugs Controller General of India ke Russian vaccine Sputnik V laga phase-3 human clinical trials lobole nemide akiya lakiya janaishe. Etu khobor toh Friday te ekta source para janaideya hisaab te ase.
Indian pharma company para Sputnik V laga trials lobole aro etu distribute koribole nemide The Russian Direct Investment Fund (RDIF) logode mela-meli ase.
Company para jowa moina koise, India te regulatory mana bechide, RDIF para drugmaker Dr Reddy ke 100 million doses debole ase.
Source koise, Dr Reddy’s Laboratories para application deya te namana agae te DCGI para application te shaijabo.
Sources koise, etu toh multi-centre, observer-blind, randomised controlled study hobole ase.
Russia te September 1 direk para Sputnik V laga phase-3 trial toh loi ase. Aro etu toh 40,000 subjects nesana te loi ase koise.
Sputnik V toh Gamaleya National Research Centre of Epidemiology and Microbiology and RDIF para bona laga ase.
Aji kali tuita vaccine candidates (tuita dawai), Bharat Biotech para ICMR logode meliken a bona aro ekta Zydus Cadila Ltd para bona toh manu ke trials lowa phase 2 te ase.
Pune-based Serum Institute of India toh Oxford COVID-19 vaccine candidate bonabo nemide AstraZeneca logode melikena ase aro tai khan be India te phase 2 aro 3 human clinical trials loi ase.
Add Comment